Clin Cancer Res: Carrelizumab + Famitinib shows effective and long-lasting anti-tumor activity in advanced renal cell carcinoma

Blocking immune checkpoints and angiogenesis is an effective treatment strategy for advanced or metastatic renal cell carcinoma (RCC)
.

This article reports an open-label, multicenter, phase 2 basket study of the efficacy and safety of carrelizumab (Camrelizumab) combined with famitinib (Famitinib) in the treatment of advanced or metastatic RCC

Immune blood vessel

In this study, the subjects were treated with carrelizumab (200 mg intravenously, 1/3 week) and famitinib (20 mg orally, 1/day)
.

The primary endpoint is the objective response rate (ORR)

Progression-free survival of the total cohort

Progression-free survival of the total cohort

A total of 38 patients were recruited, including 13 (34.
2%) newly treated and 25 (65.
8%) previously treated patients
.

The median duration from enrollment to the cut-off date was 16.

Twenty-three patients achieved a confirmed objective response with an ORR of 60.

Progression-free survival of newly treated and previously treated patients

Progression-free survival of newly treated and previously treated patients

The ORRs of newly-treated patients and previously treated patients were 84.
6% (95% CI 54.
6-98.
1) and 48.
0% (95% CI 27.
8-68.
7), respectively.
The median PFS was not reached and 13.
4 months (95% CI) 4.
1-Not reached)
.

The ORRs of newly-treated patients and previously treated patients were 84.
6% (95% CI 54.
6-98.
1) and 48.
0% (95% CI 27.
8-68.
7), respectively.
The median PFS was not reached and 13.
4 months (95% CI) 4.
1-Not reached)
.

The ORRs of newly-treated patients and previously treated patients were 84.

Partial treatment-related adverse events

Partial treatment-related adverse events

The most common grade 3-4 treatment-related adverse events were proteinuria (18.
4%), hypertension (18.
4%), decreased neutrophil count (13.
2%), palmoplantar erythema paresthesia syndrome (10.
5%) and Hypertriglyceridemia (10.
5%)
.

There were no treatment-related deaths and no new safety issues

In conclusion, carrelizumab combined with famitinib has demonstrated effective and long-lasting anti-tumor activity in patients with advanced or metastatic renal cell carcinoma (whether under initial treatment or previous treatment)

Carey natalizumab United erlotinib Method meters in patients with advanced or metastatic renal cell carcinoma (either newly diagnosed or previously treated) are effective and exhibit long-lasting anti-tumor activity Cary natalizumab combined method imatinib m Demonstrates effective and long-lasting anti-tumor activity in patients with advanced or metastatic renal cell carcinoma (whether under initial treatment or previous treatment)

Original source:

Original source:

Qu Yuan-Yuan,Zhang Hai-Liang,Guo Hongqian et al.

Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase 2 basket study in this message